Zacks Research Has Pessimistic Outlook of PCRX Q1 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Research analysts at Zacks Research dropped their Q1 2027 earnings per share (EPS) estimates for shares of Pacira BioSciences in a report issued on Tuesday, April 22nd. Zacks Research analyst R. Department now expects that the company will earn $0.59 per share for the quarter, down from their previous forecast of $0.60. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.41 per share. Zacks Research also issued estimates for Pacira BioSciences' FY2027 earnings at $2.63 EPS.

Other analysts also recently issued research reports about the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, April 8th. HC Wainwright lifted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and boosted their target price for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Barclays boosted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $26.67.

Pacira BioSciences Price Performance

PCRX traded down $0.29 on Friday, hitting $26.71. 294,083 shares of the company's stock traded hands, compared to its average volume of 981,404. The company's 50 day simple moving average is $24.55 and its 200-day simple moving average is $21.65. The firm has a market cap of $1.24 billion, a price-to-earnings ratio of -13.16 and a beta of 0.71. Pacira BioSciences has a one year low of $11.16 and a one year high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PCRX. Point72 Asset Management L.P. bought a new position in shares of Pacira BioSciences in the 4th quarter worth $20,266,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Pacira BioSciences in the 4th quarter worth $8,558,000. Balyasny Asset Management L.P. bought a new position in shares of Pacira BioSciences in the 4th quarter worth $8,180,000. Nuveen Asset Management LLC raised its position in shares of Pacira BioSciences by 109.9% in the 4th quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock worth $11,792,000 after acquiring an additional 327,754 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Pacira BioSciences by 48.9% in the 1st quarter. Assenagon Asset Management S.A. now owns 673,289 shares of the company's stock worth $16,731,000 after acquiring an additional 221,196 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.